Xeris Biopharma Holdings (NASDAQ:XERS) Chairman & CEO Paul Edick joins Natalie Stoberman from the Proactive newsroom to share details behind its research evaluation collaboration with Regeneron Pharmaceuticals (NASDAQ:REGN) for further XeriJect development.
Edick says the agreement will have Xeris using its proprietary drug-formulation platform, XeriJect, to develop ultra-highly concentrated, ready-to-use, small volume subcutaneous injections of two undisclosed monoclonal antibodies developed by Regeneron. Xeris will receive an upfront payment and potential milestone payments for preclinical achievements. Thus, Regeneron will have an option to commercially license the Xeris technology for such molecules and nominate additional molecules for reformulation and potential commercialization.